

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

This announcement is not a prospectus. Potential investors should read the prospectus dated January 29, 2026 (the “**Prospectus**”) issued by Distinct Healthcare Holdings Limited (卓正医疗控股有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, Haitong International Securities Company Limited is expected to be appointed as the stabilization manager (the “**Stabilization Manager**”), upon entering into the International Underwriting Agreement. The Stabilization Manager (or its affiliates or any person acting for it) may make purchases, over-allocate or effect transactions in the market or otherwise take such stabilizing action(s) with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or its affiliates or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days after the last day for lodging applications under the Hong Kong Public Offering.

Potential investors should note that no stabilizing action can be taken to support the price of the Shares for longer than the stabilization period, which will begin on the Listing Date and is expected to expire on March 5, 2026, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe for, and to procure subscribers for, the Hong Kong Offer Shares, are subject to termination by the Joint Overall Coordinators (for themselves and on behalf of the Underwriters) if certain events shall occur prior to 8:00 a.m. on the Listing Date. Such grounds are set out in the section headed “Underwriting” in the Prospectus. It is important that you refer to that section for further details.



Distinct Healthcare Holdings Limited
卓正医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 4,750,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 475,000 Shares (subject to reallocation)
Number of International Offer Shares	: 4,275,000 Shares (subject to reallocation and the Over-allotment Option)
Maximum Offer Price	: HK\$66.60 per Offer Share, plus brokerage fee of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: USD0.001 per Share
Stock code	: 2677

*Joint Sponsors, Joint Overall Coordinators,
Joint Global Coordinators, Joint Bookrunners, Joint Lead Managers*



國泰海通
GUOTAI HAITONG

海通國際
HAITONG



浦銀國際SPDBI

*Joint Overall Coordinators, Joint Global Coordinators, Joint Bookrunners,
Joint Lead Managers*

CMBI 招銀國際

中國銀河國際
CHINA GALAXY INTERNATIONAL

建銀國際
CCB International

Joint Global Coordinators, Joint Bookrunners, Joint Lead Managers

ICBC 工銀國際

China Renaissance 華興資本

ZTSC 中泰國際

富途證券
FUTU Securities International

Joint Bookrunners, Joint Lead Managers

XCAP
PARTNERS

富德證券
FUND SECURITIES

老虎證券
TIGER BROKERS

APPLICATION FOR LISTING ON THE STOCK EXCHANGE

The Company has applied to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option).

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on **Friday, February 6, 2026**, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on **Friday, February 6, 2026**.

IMPORTANT NOTICE TO INVESTORS FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of this Prospectus to the public in relation to the Hong Kong Public Offering.

This Prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under “HKEXnews > New Listings > New Listing Information” and our website at www.distinctclinic.com. If you require a printed copy of this Prospectus, you may download and print from the website addresses above.

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

<u>Application Channel</u>	<u>Platform</u>	<u>Target Investors</u>	<u>Application Time</u>
HK eIPO White Form service	<u>www.hkeipo.hk</u>	Applicants who would like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Thursday, January 29, 2026 to 11:30 a.m. on Tuesday, February 3, 2026 (Hong Kong time). The latest time for completing full payment of application monies will be 12:00 noon on Tuesday, February 3, 2026 (Hong Kong time).
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit an EIPO application on your behalf through HKSCC’s FINI system in accordance with your instructions.	Applicants who would <u>not</u> like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant’s stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the printed Prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an **intermediary, broker or agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses stated above.

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details on the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **HK eIPO White Form** service or the **HKSCC EIPO** channel must be for a minimum of 50 Hong Kong Offer Shares and in one of the numbers set out in the table below.

If you are applying through the **HK eIPO White Form** service, you may refer to the table below for the amount payable for the number of the Hong Kong Offer Shares you have selected. You must pay the respective maximum amount payable on application in full upon application for Hong Kong Offer Shares.

If you are applying through the **HKSCC EIPO** channel, your broker or custodian may require you to pre-fund your application in such amount as determined by the broker or custodian, based on the applicable laws and regulations in Hong Kong. You are responsible for complying with any such pre-funding requirement imposed by your broker or custodian with respect to the Hong Kong Offer Shares you applied for.

No. of Hong Kong Offer Shares applied for	Maximum amount payable ⁽²⁾ on application/ successful allotment	No. of Hong Kong Offer Shares applied for	Maximum amount payable ⁽²⁾ on application/ successful allotment	No. of Hong Kong Offer Shares applied for	Maximum amount payable ⁽²⁾ on application/ successful allotment	No. of Hong Kong Offer Shares applied for	Maximum amount payable ⁽²⁾ on application/ successful allotment
	HK\$		HK\$		HK\$		HK\$
50	3,363.58	600	40,363.00	4,000	269,086.64	40,000	2,690,866.45
100	6,727.17	700	47,090.16	4,500	302,722.47	50,000	3,363,583.06
150	10,090.74	800	53,817.33	5,000	336,358.30	60,000	4,036,299.65
200	13,454.33	900	60,544.50	6,000	403,629.97	70,000	4,709,016.26
250	16,817.91	1,000	67,271.66	7,000	470,901.63	80,000	5,381,732.88
300	20,181.50	1,500	100,907.49	8,000	538,173.29	90,000	6,054,449.49
350	23,545.08	2,000	134,543.33	9,000	605,444.95	100,000	6,727,166.10
400	26,908.67	2,500	168,179.16	10,000	672,716.61	150,000	10,090,749.16
450	30,272.24	3,000	201,814.98	20,000	1,345,433.22	237,500 ⁽¹⁾	15,977,019.49
500	33,635.83	3,500	235,450.81	30,000	2,018,149.84		

Notes:

- (1) The maximum number of Hong Kong Offer Shares you may apply for, which is 50% of the Offer Shares initially available for subscription under the Hong Kong Public Offering.
- (2) The amount payable is inclusive of brokerage, SFC transaction levy, AFRC transaction levy and the Stock Exchange trading fee. If your application is successful, the brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) or to the **HK eIPO White Form** Service Provider (for applications made through the application channel of the **HK eIPO White Form** service) while the SFC transaction levy, the Stock Exchange trading fee and the AFRC transaction levy will be paid to the SFC, the Stock Exchange and the AFRC, respectively.

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 475,000 Offer Shares (subject to reallocation), representing 10% of the total number of Offer Shares initially available under the Global Offering; and
- the International Offering of initially 4,275,000 Offer Shares (subject to reallocation and the Over-allotment Option), representing 90% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 of the Listing Rules and Chapter 4.14 of the Guide For New Listing Applicants issued by the Stock Exchange (the “**Guide**”), Offer Shares may be reallocated from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Practice Note 18 of the Listing Rules and Chapter 4.14 of the Guide for New Listing Applicants, the maximum total number of Offer Shares following such reallocation shall not exceed 712,500 Offer Shares, representing 15% of the number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

PRICING

The Offer Price will not be more than HK\$66.60 per Offer Share and is expected to be not less than HK\$57.70 per Offer Share, unless otherwise announced by our Company no later than the morning of the last day for lodging applications under the Hong Kong Public Offering, as further explained in the section headed “Structure of the Global Offering – Pricing and Allocation” in the Prospectus. Applicants under the Hong Kong Public Offering may (depending on application channels) be required to pay, on application, the maximum Offer Price of HK\$66.60 per Offer Share in addition to brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565%, amounting to a total of HK\$3,363.58 for one board lot of 50 Shares.

EXPECTED TIMETABLE⁽¹⁾

Hong Kong Public Offering commences9:00 a.m. on
Thursday, January 29, 2026

Latest time for completing electronic applications under the
HK eIPO White Form service through the designated
website www.hkeipo.hk.11:30 a.m. on
Tuesday, February 3, 2026

Application lists open11:45 a.m. on
Tuesday, February 3, 2026

Latest time for (a) completing payment for **HK eIPO White Form**
applications by effecting internet banking transfer(s)
or PPS payment transfer(s) and (b) giving **electronic**
application instructions to HKSCC 12:00 noon on
Tuesday, February 3, 2026

If you are instructing your **broker** or **custodian** who is a HKSCC Participant to apply for Hong Kong Offer Shares on your behalf, you are advised to contact your **broker** or **custodian** for the latest time for giving such instructions, which may be different from the latest time as stated above.

Application lists close 12:00 noon on
Tuesday, February 3, 2026

Expected Price Determination Date on or before 12:00 noon on
Wednesday, February 4, 2026

Announcement of the final Offer Price, the level of applications
in the Hong Kong Public Offering, the level of indications of
interest in the International Offering and the basis of allocation
of the Hong Kong Offer Shares to be published on the website
of the Stock Exchange at www.hkexnews.hk and our website
at www.distinctclinic.com by11:00 p.m. on
Thursday, February 5, 2026

Results of allocation in the Hong Kong Public Offering to be available through a variety of channels as described in “How to Apply for Hong Kong Offer Shares – B. Publication of Results,” including through:

- (1) from the “Allotment Results” page at the designated results of allocation website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult a “search by ID” function from.11:00 p.m. on
Thursday, February 5, 2026 to
12:00 midnight on
Wednesday, February 11, 2026

(2) the allocation results telephone enquiry line
by calling +852 3691 8488 between 9:00 a.m.
and 6:00 p.m. from **Friday, February 6, 2026**
to
Wednesday, February 11, 2026
on a business day

Share certificates in respect of wholly or partially successful
applications to be dispatched or deposited into CCASS
on or before **Thursday, February 5, 2026**

HK eIPO White Form e-Auto Refund payment instructions
or refund checks in respect of wholly or partially unsuccessful
applications (or wholly successful applications, if applicable)
to be dispatched on or before **Friday, February 6, 2026**

Dealings in Shares on the Stock Exchange to commence at 9:00 a.m. on
Friday, February 6, 2026

Note:

(1) All dates and times refer to Hong Kong local dates and times.

SETTLEMENT

Subject to the granting of listing of, and permission to deal in, our Shares on the Stock Exchange and our compliance with the stock admission requirements of HKSCC, our Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in our Shares on the Stock Exchange or any other date as HKSCC chooses. Settlement of any transactions between participants of the Stock Exchange is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and the HKSCC Operational Procedures in effect from time to time. All necessary arrangements have been made for our Shares to be admitted into CCASS. Investors should seek the advice of their stockbroker or other professional advisers for details of the settlement arrangements as such arrangements may affect their rights and interests.

APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9:00 a.m. on Thursday, January 29, 2026 and end at 12:00 noon on Tuesday, February 3, 2026 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
HK eIPO White Form service	<u>www.hkeipo.hk</u>	Applicants who would like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Thursday, January 29, 2026 to 11:30 a.m. on Tuesday, February 3, 2026 (Hong Kong time). The latest time for completing full payment of application monies will be 12:00 noon on Tuesday, February 3, 2026 (Hong Kong time).
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit an EIPO application on your behalf through HKSCC's FINI system in accordance with your instructions.	Applicants who would <u>not</u> like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

The **HK eIPO White Form** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions, and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

PUBLICATION OF RESULTS

The Company expects to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocations of Hong Kong Offer Shares on the Stock Exchange's website at **www.hkexnews.hk** and our website at **www.distinctclinic.com** by no later than 11:00 p.m. on **Thursday, February 5, 2026** (Hong Kong time).

The results of allocations and identification document numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the time and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares – B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum Offer Price of HK\$66.60 per Offer Share (excluding brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee payable thereon) paid on application, or if the conditions of the Global Offering as set out in the section headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded (subject to application channels), without interest.

No temporary document of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. The Share certificates will only become valid evidence of title at 8:00 a.m. on **Friday, February 6, 2026** (Hong Kong time), provided that the Global Offering has become unconditional in all respects and the right of termination described in “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” has not been exercised. Investors who trade the Shares prior to the receipt of the Share certificates or prior to the Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on **Friday, February 6, 2026**, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on **Friday, February 6, 2026**.

The Shares will be traded in board lots of 50 Shares each and the stock code of the Shares will be 2677.

This announcement is available for viewing on the website of the Company at www.distinctclinic.com and the website of the Stock Exchange at www.hkexnews.hk.

By order of the Board
Distinct Healthcare Holdings Limited
卓正医疗控股有限公司
WANG Zhiyuan
Chairman and Executive Director

Hong Kong, January 29, 2026

As of the date of this announcement, the Board comprises Mr. WANG Zhiyuan, Mr. SHI Yi as executive Directors, Mr. CAO Shaoshan, Mr. ZHANG Xiangdong, Mr. WEI Guoxing, Ms. CHEN Xiaohong, Mr. HAO Rui as non-executive Directors, and Ms. CHEN Rui, Mr. WANG Yonggang, Mr. WANG Gaofei and Dr. GAO Pingyang as proposed independent non-executive Directors.